Interpretation of the Updated Immune Checkpoint Inhibitor Clinical Practice Guidelines by CSCO in 2024
10.3870/j.issn.1004-0781.2024.08.001
- VernacularTitle:中国临床肿瘤学会《免疫检查点抑制剂临床应用指南》2024版更新解读
- Author:
Yang FU
1
;
Jun WANG
;
Yuxiao SONG
;
Bicheng ZHANG
Author Information
1. 湖北中医药大学附属襄阳医院肿瘤血液科,襄阳 441001
- Keywords:
Immune checkpoint inhibitors;
Malignant tumor;
Guidelines;
Interpretation
- From:
Herald of Medicine
2024;43(8):1181-1186
- CountryChina
- Language:Chinese
-
Abstract:
Immunotherapy,represented by immune checkpoint inhibitors(ICIs),has significantly changed the treatment status of most patients with malignant tumors.In order to regulate and guide the immunotherapy of cancer patients in China,the Chinese Society of Clinical Oncology(CSCO)has updated the Immune Checkpoint Inhibitor Clinical Practice Guidelines every year since 2020,which has been widely praised.The Version 2024 released this year has been significantly updated in terms of content,which can be summarized in five keywords as:"addition","deletion","upgrade","downgrade"and"definiteness",with the characteristic of a large overall update range,the continuous advancement of immunotherapy,continuous enrichment of combination strategies,more first-line treatment options,and excellent performance of several drugs.This article provides a point-to-point interpretation of major updates in the new guideline.
